Phathom Pharmaceuticals logo

Phathom Pharmaceuticals

PHAT | NASDAQ
Chart Builder DCF Calculator
$5.88
-$0.18 (-2.97%)
At close: Nov 16, 2026, 4:00 PM ET
$5.88
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET
-2.97%

Rating

Updated: Nov 16, 2026
55
Fundamentals Strong
Market Sentiment Neutral
Moat None
Sector Rank #189/1021 (Top 19%)

Key Statistics

Market Data

Market Cap $477.99M
1D Range
5.77 6.14
52W Range
5.08 18.08

Valuation (TTM)

PE -5.71
PB -1.37
EV/EBITDA -13.75

Valuation (NTM)

Forward PE 8.61
Forward PEG 0.08
Price Target $15.50
Loading financial charts...

Profile

Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company i...

Sector Healthcare
Industry Biotechnology
Employees 371
IPO Date Oct 25, 2019
Fiscal Year January - December

Latest News

Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026

7 months ago · globenewswire.com

Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026
Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026

9 months ago · globenewswire.com

Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026

Earnings

Latest Earnings
Oct 29, 2026
EPS
-$0.16
Miss -45.85%
REV
$84.72M
Miss -0.12%
Next Earnings
Feb 25, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
4
Consensus
Buy
Price Target
$15.50
Upside
+163.61%
Buy (4)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.